Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uPAR PET/CT and FDG PET/MRI in Bladder Cancer
NCT02805608Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of 68Ga-NOTA-AE105 in bladder cancer, sponsored by Rigshospitalet. Primary endpoints: uPAR PET/CT: regional lymph node metastases at 1 hour and FDG PET/MRI: regional lymph node metastases at 1 hour. Status: unknown.
02
Drugs
68Ga-NOTA-AE105
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02805608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805608.